drugset / Trial / NCT02036164
Adjuvant Chemotherapy for Locally Advanced Cervical Cancer
Phase 3
Unknown
500 enrolled
Siriwan Tangjitgamol, MD
Bhumibol Adulyadej Hospital · collabChiang Mai University · collabChonburi Cancer Hospital · collabHealth Intervention and Technology Assessment Program · collabLampang Cancer Hospital · collabLopburi Cancer Hospital · collabNational Research Council of Thailand · collabNavamindradhiraj University · collabPrince of Songkla University · collabRajburi Hospital · collabUbonratchathani Cancer Hospital · collabUdonthani Cancer Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Data of survival benefit from adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) for locally advanced cervical cancer (LACC) are still limited and inconsistent. We will investigate if ACT has survival benefit over CCRT alone.
Timeline
- Start
- 2014-01
- Primary completion
- 2018-01
- Completion
- 2019-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |